Market Closed -
Nasdaq
04:30:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
4.16
USD
|
-1.19%
|
|
+5.85%
|
+18.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
162.4
|
266.3
|
232.4
|
407.6
|
206.5
|
247.2
|
-
|
-
|
Enterprise Value (EV)
1 |
162.4
|
266.3
|
18.08
|
407.6
|
206.5
|
247.2
|
247.2
|
247.2
|
P/E ratio
|
-2.59
x
|
-6.18
x
|
-3.74
x
|
-6.57
x
|
-5.48
x
|
80
x
|
-9.77
x
|
-15.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
7.45
x
|
9.98
x
|
4.33
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
7.45
x
|
9.98
x
|
4.33
x
|
EV / EBITDA
|
-
|
-
|
-4.15
x
|
-6.53
x
|
-
|
-6.44
x
|
-5.84
x
|
-8.68
x
|
EV / FCF
|
-
|
-7.1
x
|
-4.13
x
|
-8.04
x
|
-4.93
x
|
-7.1
x
|
-4.19
x
|
-5.35
x
|
FCF Yield
|
-
|
-14.1%
|
-24.2%
|
-12.4%
|
-20.3%
|
-14.1%
|
-23.9%
|
-18.7%
|
Price to Book
|
-
|
4.46
x
|
1.13
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,953
|
38,820
|
58,092
|
58,560
|
58,822
|
59,414
|
-
|
-
|
Reference price
2 |
5.810
|
6.860
|
4.000
|
6.960
|
3.510
|
4.160
|
4.160
|
4.160
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
33.17
|
24.78
|
57.03
|
EBITDA
1 |
-
|
-
|
-55.96
|
-62.42
|
-
|
-38.4
|
-42.36
|
-28.49
|
EBIT
1 |
-63.07
|
-36.42
|
-56.22
|
-62.68
|
-42.79
|
-26.27
|
-43.95
|
-31.67
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-79.21%
|
-177.37%
|
-55.53%
|
Earnings before Tax (EBT)
1 |
-62.14
|
-38.03
|
-57.78
|
-62.02
|
-37.54
|
-11.72
|
-40.74
|
-27.23
|
Net income
1 |
-60.83
|
-37.55
|
-57.78
|
-62.02
|
-37.54
|
4.723
|
-25.85
|
-17.46
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
14.24%
|
-104.34%
|
-30.62%
|
EPS
2 |
-2.240
|
-1.110
|
-1.070
|
-1.060
|
-0.6400
|
0.0520
|
-0.4260
|
-0.2667
|
Free Cash Flow
1 |
-
|
-37.49
|
-56.29
|
-50.7
|
-41.92
|
-34.8
|
-59
|
-46.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-104.92%
|
-238.12%
|
-81.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
23.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-9.333
|
-8.827
|
-10.47
|
-11.66
|
EBIT
1 |
-15.4
|
-16.48
|
-17.71
|
-14.78
|
-13.7
|
-16.8
|
-10.34
|
-9.55
|
-6.098
|
-9.394
|
-9.51
|
-10.74
|
-10.98
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.71%
|
Earnings before Tax (EBT)
1 |
-15.75
|
-16.79
|
-17.78
|
-14.55
|
-12.9
|
-15.62
|
-8.987
|
-8.187
|
-4.753
|
-8.082
|
-9.57
|
-10.33
|
-10.98
|
Net income
1 |
-15.75
|
-16.79
|
-17.78
|
-14.55
|
-12.9
|
-15.62
|
-8.987
|
-8.187
|
-4.753
|
-8.082
|
-9.57
|
-10.33
|
-10.96
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.65%
|
EPS
2 |
-0.2700
|
-0.2900
|
-0.3000
|
-0.2500
|
-0.2200
|
-0.2700
|
-0.1500
|
-0.1400
|
-0.0800
|
-0.1400
|
-0.1650
|
-0.1825
|
0.2967
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/5/22
|
8/5/22
|
11/10/22
|
3/9/23
|
5/4/23
|
8/3/23
|
11/3/23
|
3/7/24
|
5/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
214
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-37.5
|
-56.3
|
-50.7
|
-41.9
|
-34.8
|
-59
|
-46.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-43.6%
|
-34.8%
|
-27.7%
|
-39%
|
-27.6%
|
-13.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.540
|
3.540
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
-
|
0.01
|
0.02
|
-
|
-
|
2.8
|
3.3
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
11.3%
|
5.79%
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
4.16
USD Average target price
9.25
USD Spread / Average Target +122.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.52% | 247M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|